Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

 in the US remain untreated after being diagnosed, new data suggest, while patients who are treated often report short treatment durations and highly variable care patterns.

These ongoing gaps in standardized management strategies for vitiligo were highlighted in a recent analysis published in 

. Investigators, led by Roni Adiri, PhD, of Pfizer Pharmaceutical Israel LTD, conducted this recent retrospective cohort analysis to explore the demographic and clinical characteristics of those living with vitiligo, as well as how approaches to therapy differ according to age and disease extent.

“Leveraging linked electronic health records (EHRs) and claims data in the US, this study characterizes demographics, clinical characteristics, and treatment patterns in patients with vitiligo, overall and by vitiligo extent and age,” Adiri and colleagues wrote.

The analysis used de-identified data drawn from the linked Komodo Healthcare Map and OMNY Health Foundation databases. These databases combine electronic health record information with medical and pharmacy claims from US 

 clinics and broader health care settings across the country.

Adiri et al identified individuals whose first documented vitiligo diagnosis took place in the timeframe between January 2018 - August 2023. Those involved as subjects were required to have at least a single year of continuous health plan enrollment prior to their index diagnosis date. Otherwise, they needed an equivalent eligibility proxy in the case of open claims data, along with 3 months at least of follow-up after diagnosis.

Participants without age information or follow-up data were not included. Those included in Adiri and coauthors’ analysis were categorized based on their age and the percentage of body surface area (BSA) impacted by vitiligo at the point of baseline. They grouped patients’ disease extent into involvement of 10% BSA or less, over 10% BSA, or no documented BSA evaluation at index. Their data analysis was carried out between April - August 2024.

Which Patterns Were Identified in Patients with Vitiligo?

The final study population included 24,949 individuals with vitiligo. However, only 5.3% of the cohort were shown to have a documented BSA assessment at the time of their diagnosis. Among subjects with recorded disease extent, 963 of these patients showed 10% or less BSA involvement. 366 were noted to have more extensive disease affecting over 10% BSA.

88.2% those included in the cohort were adults aged 18 years or older and 56.3% were female. Among those with available data regarding lesion location, facial involvement was the most commonly reported manifestation, appearing in roughly one-third of observed cases. Although there are chronic and often psychosocial burdens linked vitiligo, a notable proportion of those assessed did not receive treatment during their follow-up interactions.

 Depending on BSA subgroup, Adiri and colleagues noted between 27% - 32% of patients remained untreated following their diagnosis.

The investigators also observed the highest untreated proportion to be participants showing limited disease involvement. Among the individuals who did receive treatment, topical and systemic corticosteroids represented some of the most frequently utilized agents. Topical calcineurin inhibitors and phosphodiesterase-4 (PDE4) inhibitors were also commonly prescribed. The team further noted the similarity between treatment patterns, regardless of disease extent, with few meaningful distinctions noted between BSA categories.

However, Adiri et al did find age-related differences in management. Children and adolescents were found to be more likely to receive topical drugs, whereas adults more commonly received systemic medications. The investigative team additionally found considerable heterogeneity in sequencing of treatments for vitiligo, suggesting a lack of consistent therapeutic pathways in routine practice settings.

Treatment persistence also appeared limited. Adiri and coauthors described median duration of therapy as ranging from approximately 1.8 months to 4.1 months across first- and second-line treatment regimens. This depended on the therapeutic modality implemented.

What Can We Conclude About Vitiligo in the US?

Overall, the investigators’ data point to significant variability in the way vitiligo is managed in clinical practice and suggest many individuals with vitiligo may not be receiving sustained or standardized care. In the team’s conclusion, these real-world insights were described as helping to guide future research efforts and inform strategies designed to improve outcomes for those living with vitiligo.

Adiri R, Gauthier G, Kurosky SK, et al. Clinical Characteristics and Treatment Patterns in Patients With Vitiligo. JAMA Dermatol. Published online May 06, 2026. 

Seneschal J, Speeckaert R, van Geel N, et al. Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the international Vitiligo Task Force-Part 2: Specific treatment recommendations. J Eur Acad Dermatol Venereol. 2023 Nov;37(11):2185-2195. 

Articles

Linked US EHR and claims data from 2018–2023 show substantial care gaps and heterogeneity in vitiligo management. In a cohort of 24,949 patients, baseline disease extent was rarely documented, with body surface area recorded for only 5.3%. Across disease-extent strata, 27%–32% received no treatment during follow-up, particularly those with limited involvement. When treated, regimens frequently relied on topical/systemic corticosteroids, calcineurin inhibitors, and PDE4 inhibitors, with short median persistence across lines of therapy.

This large real-world analysis of patients with vitiligo suggests many individuals remain untreated after diagnosis.

Vitiligo

Vitiligo condition center page is a comprehensive resource for clinical news and insights on the dermatologic condition. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for the affected skin of vitiligo patients.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Key Characteristics, Treatment Patterns Identified in Patients with Vitiligo

Mehdi Shishehbor, DO, PhD, is the president of the Harrington Heart & Vascular Institute at University Hospitals.

PROMISE III: Substantial Amputation-Free Survival With LimFlow TADV in CLTI

Primary 6-month data from the PROMISE III study of transcatheter arterialization of the deep veins (TADV) with the LimFlow System has shown 86% limb salvage and 80.7% amputation-free survival in patients with 

no-option chronic limb-threatening ischemia (CLTI)

These data were presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 2026 Scientific Sessions in Montreal, Quebec, by Mehdi Shishehbor, DO, PhD, president of the Harrington Heart & Vascular Institute at University Hospitals. The editorial team at

 spoke with Shishehbor to discuss the broader implications of this study for patients with CLTI.

“These are folks with gangrene and ulcers, with diabetes and vascular disease, at risk of major amputation, and they are considered not eligible for standard therapies of revascularization, meaning endovascular or surgical bypass,” Shishehbor told 

. “So when you’re talking about 86% limb salvage in a cohort of patients that have no option, that’s pretty good odds. That’s a pretty good outcome.”

PROMISE III is an ongoing prospective, single-arm, multi-center study aiming to provide additional information on the LimFlow System for creating an AV connection in the Below The Knee (BTK) vascular system via an endovascular, minimally invasive approach to arterialize the pedal veins. The study was conducted across 30 locations in the US and is expected to continue out to 12 months of follow-up.

Patients were eligible for inclusion if they had a clinical diagnosis of CLTI with Rutherford Classification 5, ischemic ulceration, or Rutherford Classification 6, ischemic gangrene. Additionally, the Target In-flow Artery at the cross-over point had to fall within the recommended diameter ranges for the LimFlow stent graft, and patients had to have stable glycemic control, among other criteria. Patients were excluded if they had concomitant hepatic insufficiency, thrombophlebitis in the target limb, absence of adequate tissue in the target foot, or active immunodeficiency disorders, among other criteria.

The study’s primary outcome is amputation-free survival, defined as freedom from major above-ankle amputation and all-cause mortality, at 6 months. Secondary outcomes included primary and secondary patency at 30 days and 6 months, limb salvage at 30 days, 3 months, and 6 months, change in Rutherford classification at 30 days, 3 months, and 6 months, and target wound healing at 30 days and 3, 6, and 12 months, among others.

A total of 100 patients, resulting in 103 limbs, were enrolled in the study and underwent TADV. All 103 had non-healing ulcers or gangrene, of which 74.8% were Rutherford class 5 and 25.2% were class 6. By 6 months, the primary endpoint of amputation-free survival was 80.7%, while limb salvage was 86.5% and survival was 93.8%. Roughly 80% of all wounds had either completely healed or were healing.

Shishehbor and colleagues also noted a median pain score of 2.0 at 6 months, which had substantially dropped from a baseline of 6.0 (

 <.0001). Significant improvements were also recorded in quality-of-life metrics at 6 months versus baseline, including concerns about poor circulation, ability to fall or stay asleep, feeling burdened by the wound, and ability to participate in social activities.

“We are very proud and very excited, and this builds on other data that we have had,” Shishehbor said. “We have had PROMISE I, PROMISE II, PROMISE UK, and now PROMISE III, and they just show that we’re doing a little bit better each time.”

Editors’ Note: Shishehbor reports serving as a consulting and advisory board for ANT, Inquis, Abbott Medical, Medtronic, Boston Scientific, and Inari.

Shishehbor M. PROMISE III: 6-Month Clinical and Quality of Life Outcomes in CLTI Patients Treated with Transcatheter Arterialization of the Deep Veins. Presented at the Society for Cardiovascular Angiography and Interventions 2026 Scientific Sessions, Montreal, Quebec. April 23-25, 2026.

LimFlow, Inc. PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia. ClinicalTrials.gov Identifier: NCT05313165. Updated April 16, 2026. Accessed May 12, 2026. 

https://clinicaltrials.gov/study/NCT05313165

Videos

Mehdi Shishehbor, DO, PhD, discusses the 6-month results from his recent study, confirming the efficacy of the LimFlow System in patients with CLTI.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Venous Thromboembolism

The HCPLive venous thromboembolism page is a resource for medical news and expert insights on VTE. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for thrombotic disease, and more.

Practicing critical care pulmonologist, Managing Director of Health Innovation at Manatt, medical analyst for NBC News and MSNBC, affiliate faculty at the University of Washington's Institute for Health Metrics and Evaluation, commissioned officer (Major) in the United States Air Force Medical Reserve Corps, and board member of the American Lung Association

Eyes on Chronic Air Pollution, With Vin Gupta, MD, MPA

's 2026 State of the Air report — finding that 152.3 million Americans, or 44% of the population, live in counties with failing grades for at least one air pollutant — lands at a moment when public attention to air quality tends to focus on dramatic acute events, while the more chronic and clinically significant burden goes underappreciated. 

sat down with Vin Gupta, MD, MPA, a practicing critical care pulmonologist at Virginia Mason Medical Center, Managing Director of Health Innovation at Manatt, medical analyst for NBC News and MS NOW (formerly MSNBC), and affiliate faculty at the University of Washington's Institute for Health Metrics and Evaluation, who argues to bring attention back to the slow burn chronic impacts of poor air quality and how it should impact both clinician and patient behavior.

Gupta, who also serves as a commissioned officer (Major) in the United States Air Force Medical Reserve Corps and board member of the ALA, noted that acute wildfire smoke events — including the devastating Los Angeles–area fires of early 2025 — command media attention and public alarm in ways that chronic ozone and particulate matter exposure do not. That disparity in attention, he argued, distorts public and policy understanding of where the sustained health burden actually lies. The 2026 report found that nearly half of American children — 33.5 million, or 46% of those under 18 — live in counties receiving a failing grade for at least one pollution measure, and that approximately 4 million more people are now breathing unhealthy ozone levels compared with last year's report. These are not acute exposure events but chronic conditions with cumulative biological consequences: impaired lung development in children, increased cardiovascular risk, and higher rates of respiratory exacerbations in patients with existing pulmonary disease. Gupta observed that patients, like those who feel well and skip hypertension or cancer screening, frequently fail to connect their chronic disease trajectory to the air quality of their zip code precisely because the exposure is invisible, odorless, and without a dramatic triggering event.

On Environmental Protection Agency (EPA) regulatory rollbacks — including the removal of health costs from economic analyses used to set pollution standards — Gupta was direct about his assessment of near-term impact: he does not expect clinical advocacy to change the current administration's environmental policy priorities. The more realistic and valuable role for the clinical community, in his view, is public education that is deliberately apolitical — presenting facts about pollution-related health harm in ways that reduce rather than reinforce existing ideological divides. His particular emphasis was on children: more than 7 million children live in communities with failing grades for all 3 pollution measures, and developing lungs are uniquely and irreversibly vulnerable to chronic pollution exposure. Short of environmental policy at scale, he argued, individual-level mitigation strategies — indoor air filtration, activity modification on poor air quality days — are inherently partial solutions. The longer-term opportunity, he suggested, lies in shaping how voters prioritize environmental health policy in future election cycles, and that doing so requires the clinical community to communicate these issues with persuasion rather than provocation.

“This could as an opportunity to change how people think about environmental regulation policies as it pertains to their health in future election cycles… I think we have to get better on how to talk about these issues without triggering people and their pre existing biases, because a lot of this stuff becomes… nonsensical,” Gupta said. “This is not limited to climate and health or environment and health, but sort of all potentially controversial issues in healthcare [that] become distorted and politicized. And so I do hope that the State of the Air report allows us to reset on what's happening, why is it happening, and who is it impacting?”

American Lung Association. State of the Air 2026. 27th ed. Published April 21, 2026. Accessed May 12, 2026. 

Gupta discusses clinical responsibility in response to the ALA's State of the Air 2026 report.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Strategic Alliance Partnership

Erin Ferranti, PhD, MPH, is an associate professor at the Nell Hodgson Woodruff School of Nursing at Emory University and the director of the Farmworker Family Health Program.

New AHA Recommendations Encourage Improving Postpartum Cardiovascular Care

A recent publication from the American Heart Association (AHA) has provided a set of guidelines and tools to optimize postpartum heart health for women.

, fetal growth restriction, and others can portend a higher risk of future long-term complications, including greater lifetime risk of 

atherosclerotic cardiovascular disease (ASCVD)

. These risks are further exacerbated by disparities in socioeconomic status, geography, and race and ethnicity.

“Particularly, one of the big things we’re trying to push for is to get everybody to ask a woman if she’s given birth recently,” Erin Ferranti, PhD, MPH, associate professor at the Nell Hodgson Woodruff School of Nursing at Emory University, director of the Farmworker Family Health Program, and co-author on the AHA recommendations, told 

 in an exclusive interview. “When you present in urgent care or an ER, that may not be one of the first questions providers think to ask, but if a woman presents with high blood pressure, it’s a critical question to know. That first week to two weeks post-delivery could be a very dangerous time period.”

The new recommendations aim to provide a pathway for evidence-based care implementation during the postpartum phase, which has been historically overlooked in its potential for cardiovascular risk. The present document is its second iteration following a secondary literature review and ongoing dialogue with clinical and community organizations. The recommendations are collected into 4 major points: standardizing postpartum systems, interdisciplinary care and engagement, advocacy and policy expansion, and risk factor identification and monitoring.

Recommendation 1: Standardizing Postpartum Systems

The crux of this first recommendation is the education of both patients and specialists on the risks of cardiovascular disease postpartum, encouraging outreach from clinicians to schedule follow-up visits after delivery and suggesting further training in cardio-obstetrics. The recommendations stress that a functional cardio-obstetrics team requires cardiologists, obstetricians, maternal-fetal medicine specialists, primary healthcare providers, geneticists, pharmacists, obstetric anesthesiologists, neonatologists, and a list of other members to maximize commitment and effective communication.

Recommendation 2: Interdisciplinary Care and Engagement

This segment of the document focuses on policy gaps, such as Medicaid reimbursement and training reimbursement, as well as referral pathways between hospitals and providers to enhance access to postpartum care. Hospitals are encouraged to select care team members to serve as “care champions”, who will establish and maintain regular communication with community partners.

Additionally, this section emphasizes the value of including family members and partners into postpartum education, fostering shared responsibility. Peer support groups, community-based organizations, and other options are also cited.

Recommendation 3: Advocacy and Policy Expansion

The backbone of this segment is the belief that US Federal law should require all states to provide Medicaid coverage through the first 12 months following birth to all patients who meet the Federal Poverty Level guidelines, including in-office, telehealth, home visits, emergency department, and urgent care visits. The writers suggest that clinicians develop educational and informational guidelines to disseminate among all obstetric clinicians who provide care to postpartum patients, as well as with potential stakeholders across the country.

Recommendation 4: Risk Factor Identification and Monitoring

The final suggestion advises clinicians to establish definitive strategies and mechanics for risk factor identification in postpartum patients. This includes advising clinicians of the increased cardiovascular disease risk after birth and the need for risk stratification to guide management algorithms. Additionally, factors such as the signs and symptoms of cardiovascular disease during pregnancy potentially imitating physiological changes of pregnancy are emphasized.

This section also highlights the importance of establishing health care systems that are sensitive to and regularly screen for social determinants of health that could limit care access or quality. Additionally, the document suggests that women with cardiovascular disease be evaluated prior to conception for discussions about risks, optimization of their cardiovascular health, and the need for regular surveillance.

“We traditionally have been very much in silos – endocrinology has their shop and cardiology has their shop, and we haven’t built systems that integrate our specialties well,” Ferranti said. “It has to come from the system to make those collaborations as priority. They need to be seamless. We need to have handoffs from provider to provider, specialty to specialty, so that women are not navigating these silo specialties on their own.”

Editors’ Note: Ferranti reports no relevant disclosures.

Bond R, Ferranti E, Lehnert T, et al. Advancing Maternal Health: Postpartum Care Recommendations and Resources Toolkit. 

https://www.heart.org/en/-/media/Files/Professional/Quality-Improvement/Maternal-Health/AHA_Advancing-Maternal-Health-Toolkit_FINAL_0426.pdf?sc_lang=en

Lewey J, Beckie TM, Brown HL, et al. Opportunities in the postpartum period to reduce cardiovascular disease risk after adverse pregnancy outcomes: A scientific statement from the American Heart Association. Circulation. 2024;149(7). 

Erin Ferranti, PhD, MPH, discusses the new guidelines and their implications for continued enhancement of both access to and outcomes of postpartum care.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Atherosclerotic Cardiovascular Disease

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

US Food and Drug Administration (FDA) Commissioner Marty Makary, MD, MPH, resigned from his position on May 12, 2026, following weeks of reports that the Trump administration was planning his removal. Kyle Diamantas, JD, the Agency's Deputy Commissioner for Food, has been named acting commissioner while a permanent replacement is identified.

The resignation marks one of the fastest commissioner departures in modern FDA history. Makary served in the role for just over a year, having been confirmed on March 25, 2025, by a bipartisan vote of the US Senate as the 27th Commissioner of Food and Drugs.

Reports of Makary's potential exit emerged publicly in early May after the Wall Street Journal and other outlets reported that US President Donald Trump had authorized a plan to remove him. According to Newsmax, citing the Wall Street Journal, Trump grew frustrated with Makary over delays related to flavored vaping products.

Sources within HHS had reportedly been exploring ways to remove Makary for months prior to his departure. His tenure was marked by internal disagreements, complaints from regulated industries, and staff turnover across several program areas.

Prior to leading the FDA, Makary was a surgical oncologist and chief of Islet Transplant Surgery at Johns Hopkins University School of Medicine, where he held an endowed chair in gastrointestinal surgery and was a full professor with tenure.

During his tenure, Makary advanced several positions that drew significant attention from the medical and scientific communities, including calls for large placebo-controlled trials of COVID-19 vaccines in lower-risk age groups and policy shifts in the Agency's approach to drug approvals. In May 2025, Makary and Center for Biologics Evaluation and Research (CBER) Director Vinay Prasad, MD, published a perspective in the New England Journal of Medicine announcing that the FDA would restrict COVID-19 vaccine recommendations to adults 65 years of age and older or those at high risk of serious illness, while requiring manufacturers to conduct additional studies evaluating vaccine benefits in children and healthy younger adults.

Makary's time at the Agency also coincided with significant workforce reductions, turnover among senior staff, and ongoing debate about the appropriate role of regulatory and scientific independence at the FDA.

Diamantas brings a legal and policy background to the acting commissioner role. As Deputy Commissioner for Food, he led the FDA's Human Foods Program, overseeing nutrition and food safety activities, resource allocation, and risk-prioritization strategy. He has also served as a liaison between the FDA, HHS, and the White House, and has represented the Agency in dealings with foreign governments and international organizations.

Names reported to be under consideration for the permanent commissioner role include former FDA Commissioner Stephen Hahn, MD, who led the Agency from 2019 to 2021, and former Acting Commissioner Brett Giroir, MD.

For clinicians, the period of transition raises practical questions about the pace and predictability of therapeutic approvals, vaccination policy guidance, and regulatory decision-making across FDA centers, several of which are currently operating under acting leadership. The direction a permanent commissioner will bring to these functions remains to be seen.

STAT News. FDA Commissioner Marty Makary resigns, replaced by Kyle Diamantas. May 12, 2026.

 Accessed May 12, 2026. https://www.statnews.com/2026/05/12/fda-commissioner-marty-makary-resigns-kyle-diamantas-acting/

FDA. Martin A. Makary, MD, MPH, Sworn in as FDA Commissioner. April 2025.

 Accessed May 12, 2026. https://www.fda.gov/news-events/press-announcements/martin-makary-md-mph-sworn-fda-commissioner

Pharmaceutical Executive. President Trump Planning to Fire FDA Commissioner Marty Makary: Report. May 2026.

 Accessed May 12, 2026. https://www.pharmexec.com/view/president-trump-planning-fire-fda-commissioner-marty-makary-report

FDA. Kyle Diamantas J.D. April 9, 2026. Accessed May 12, 2026. 

https://www.fda.gov/about-fda/fda-organization/kyle-diamantas

FDA Commissioner Marty Makary resigned May 12, 2026, after roughly one year in the role, with Kyle Diamantas appointed acting commissioner. His departure followed reports of White House plans to remove him, reportedly tied to frustration over flavored vaping-product delays, amid broader internal discord, industry complaints, and staff turnover. Makary, a Johns Hopkins surgical oncologist, drew national attention for proposing more stringent evidentiary standards for COVID-19 vaccination in lower-risk groups and for broader shifts in approval posture. Leadership succession remains unsettled.

After roughly 14 months leading the agency and recent reports of the Trump administration planning his removal, FDA Commissioner Marty Makary, MD, MPH, has resigned.

FDA News

Internal Medicine

Internal Medicine condition center page, resources on the topics of medical news and expert insight into internal medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on internal medicine research, treatment, and drug development.

Hospital Medicine

The HCPLive hospital medicine page is a comprehensive resource for clinical news and insights on the emergency medicine specialty. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for emergent care, and more.

FDA Commissioner Marty Makary Resigns, Kyle Diamantas Steps In as Acting Head

A study suggested lumateperone demonstrated favorable efficacy outcomes and limited weight gain and akathisia risk compared with other adjunctive antipsychotics for MDD.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Lumateperone Ranked Favorably Among Adjunctive MDD Therapies, With Leslie Citrome, MD

Seemal R. Desai, MD, and Pearl E. Grimes, MD, discuss the complexities of colorism and its impact on pigmentary disorders.

Discussing Colorism and Pigmentary Disorders, With Seemal Desai, MD, and Pearl Grimes, MD

Christopher Brooks, MD, an allergy and immunology physician at The Ohio State University.

In this Q&A, Christopher Brooks, MD, discusses advancing research on intralymphatic immunotherapy for environmental and, more recently, food allergies.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Food Allergy

How Close Is Intralymphatic Immunotherapy for Food Allergies?

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

The NDA submission follows positive results from the CALIBRATE phase 3 trial, which evaluated encaleret versus standard-of-care in adults with ADH1.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Thyroid Disorders

BridgeBio Submits NDA for Encaleret for Autosomal Dominant Hypocalcemia Type 1

Mitapivat has been submitted to the FDA for accelerated approval in sickle cell disease after phase 3 results showed a hemoglobin benefit.

Sickle Cell

Sickle Cell condition center page, resources on the topics of medical news and expert insight into sickle cell disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sickle cell research, treatment, and drug development.

Mitapivat sNDA Seeks FDA Accelerated Approval in Sickle Cell Disease

Sameh Sayfo, MD, is the program director of the Endovascular Intervention Fellowship at the Heart Hospital Baylor Plano and an interventional cardiology and peripheral endovascular specialist at Baylor Scott & White Health.

Sameh Sayfo, MD, discusses his recent analysis of the DETOUR2 study, highlighting the efficacy of the DETOUR system for patients regardless of runoff.

Structural Heart Disease

RODEO-PTAB: PTAB Benefits Independent of Number of Runoff Vessels

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

New OX40 biologics aim for longer atopic dermatitis control, but Kaposi's sarcoma concerns split experts as amlitelimab advances and rocatinlimab halts.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

OX40 Targeting in Atopic Dermatitis: A Pathway Under Scrutiny

Findings suggest potential value in complete blood count (CBC)-derived parameters for assessments of hidradenitis suppurativa (HS) disease activity and severity.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Correlation Identified Between Complete Blood Count Parameters, HS Severity

Mauro Cancian, MD, PhD, head of the allergy division at the University of Padua.

Experts weigh in on a rapidly evolving treatment landscape, from a first-line oral option to a one-time CRISPR therapy showing 87% attack reduction.

HAE in 2026: New Therapies, Updated Guidelines, the Case for Early Treatment

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Catch up on the hematology news and data you missed from April 2026. 

Latest News

Key Characteristics, Treatment Patterns Identified in Patients with Vitiligo

PROMISE III: Substantial Amputation-Free Survival With LimFlow TADV in CLTI

Eyes on Chronic Air Pollution, With Vin Gupta, MD, MPA

New AHA Recommendations Encourage Improving Postpartum Cardiovascular Care

FDA Commissioner Marty Makary Resigns, Kyle Diamantas Steps In as Acting Head